Cell Viability Assays Market Size & Share, Growth Analysis 2036

Global Market Size, Forecast, and Trend Highlights Over 2024 - 2036

Cell Viability Assays Market size is expected to surpass USD 19.7 Billion by the end of 2036, growing at a CAGR of 11.5% during the forecast period, i.e., 2024 – 2036. In the year 2023, the industry size of cell viability assays was over USD 5 Billion. The market growth is due to growing interest in developing cell therapy technologies for the treatment of COVID-19 and its increasing acceptance. For example, in 2020, Calidi Biotherapeutics Inc. announced that the Food and Drug Administration had granted provisional marketing authorization for its partner Personalized Stem Cells Inc.'s Investigational New Product Application to be used with stem cell therapy on COVID-19 and pneumonia patients. COVID-19 was reported to WHO by 761,769,759 confirmed cases including 6,784,181 deaths across the globe.

In addition, investment in the area of cell-based research and funding has increased. For example, the California Center for Regenerative Medicine said in February 2022 that it would invest around USD 10 million on a cell therapy study to help patients who have throat cancer recover from terrible radiation side effects.

Cell Viability Assays Sector: Growth Drivers and Challenges

Growth Drivers

Growing Geriatric Population- By 2030, one in six people on the earth would be 60 years of age or older, according to the World Health Organisation. There will likely be 1.4 billion persons who are 60 years of age or older by 2022, up from 1 billion in 2020. Cells make up the majority of tissues. All cells alter as they become older. They are growing larger while losing the ability to divide and multiply. Inside the cells, there are a number of pigments and fatty substances as well as other modifications. With increasing age, many of the cells stop functioning properly or start working in an unnatural way.
Rise in Prevalence of Cancer- During the forecast period, an increase in cancer patients is anticipated. According to the World Health Organization, almost 10 million deaths, or roughly one in six deaths, would be caused by cancer in 2020, making it the top cause of death globally.
Surge in Need for Stem Cell Transplant- A total of 12,000 stem cell transplants have taken place around the world in the last 50 years. Around 49,000 transplants have already been performed each year, and the number is growing.

Challenges

Shortage of Technical Specialists and Professionals to Run Instruments- The global shortage of healthcare professionals can be attributed to the fact that many countries do not invest in health worker education and training. The lack of alignment between employment and education policies in view of the needs of workers and healthcare systems is also a major issue. The situation has deteriorated further since healthcare personnel is difficult to bring into remote, underutilised areas and in the countryside. In addition, there has been an increase of health workers' migration that could lead to a shortage in particular for poor and less well-developed countries.
Assays for the Viability of Cells are very Expensive which may Hinder the Growth of the Market
Misunderstanding of People's Awareness is One of the Retraining Factor

Cell Viability Assays Segmentation

Application (Drug Discovery & Development, Stem Cell Research)

The stem cell research is anticipated to account for 52% share of the global cell viability assays market during the forecast period. The growth of this category can be attributed to increasing investments in stem cell research, and the Novo Nordisk Foundation's investment is expected to reach as high as USD 340 million over 10 years for the construction of a global Stem Cell Research Facility by 2022. The growth segment is also projected to benefit from an increase in the incidence of cardiovascular disease. The problems with the blood vessels cause cardiac disease most of the time. Stem cells that appear and function as normal blood vessels are used for the production of new blood vessels. In view of their ability to repair or regenerate various human tissues, stem cells from the bank can be used as a tool for people who are affected by conditions like vascular and cardiac disease.

Product (Consumables, Instrument)

Cell viability assays market from the consumables segment is expected to hold the largest share by the end of 2036. In view of the application of consumables for diagnostics, stem cell research, and pharmaceutical and biopharmaceutical research in particular, this segment is expected to experience significant growth with approximately 55 % market share over the forecast period. A large selection of nontoxic, ready-to-use, and highly immediate results reagents for cell viability assays is also available from a number of market participants.

Our in-depth analysis of the global market includes the following segments:

Product	Consumables Instrument
Application	Drug Discovery & Development Stem Cell Research

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cell Viability Assays Industry - Regional Synopsis

North American Market Forecast

North America region is projected to account for 38% share of the cell viability assays market, supported by an increase in cancer cases and infrastructure for clinical and laboratory research with a quality that has not yet been achieved in North America. a projected 1,806,590 new instances of cancer were identified in the US in 2020, while 606,520 people passed away from the illness. Consequently, it is expected that growth in the product market will be driven by demand for cell-based therapies. The expansion of the research and development capability, coupled with increasing expenditure on developing healthcare infrastructure, has led to a growing need for cell viability assays.

APAC Market Statistics

The cell viability assays market in Asia Pacific is attributed to have about 28% share during the forecast period. The growth of the market may be due to a growing government initiative, which seeks to inform people about an increasing incidence of cancer and different types of cell therapy available. In addition, the government in these areas makes a great deal of investment in research and development. However, cell therapies such as stem cell therapy are also being funded by a variety of private sectors. Consequently, the growth of the market in this region is estimated to be stimulated by these factors. In addition, the growth of this industry is projected to be driven by an increase in demand for biopharmaceutical products as well as a presence of cutting-edge research and healthcare infrastructure throughout the region.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Cell Viability Assays Landscape

Thermo Fisher Scientific Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Agilent Technologies, Inc.
Bio-Rad Laboratories Inc.
Merck KGaA
Becton, Dickinson and Company (BD)
PerkinElmer Inc.
Promega Corporation
Biotium, Inc.
Creative Bioarray
Abcam Plc.

In The News

The improved applied Biosystems HIV-1 Genotyping Kit was released by Thermo Fisher Scientific, Inc. The new kit complements the previously released Applied Biosystems MagMax Viral/Pathogen Nucleic Acid Isolation Kit for HIV-1 Blood Sports. With the aid of this device, labs may monitor HIV mutations to antiretroviral treatment inhibitors using a cutting-edge method for drug resistance surveillance.
The BD Rhapsody TCR/BCR Multiomic Assay, a cutting-edge set of reagents that enables researchers to more easily and thoroughly analyze crucial immune system cells, was released by BD (Becton, Dickinson, and Company), a leading global medical technology company. This assay would then be used to advance research on autoimmune disorders, immune oncology, and infectious diseases.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the cell viability assays market?

Ans: The majority factors driving the growth of the market are growing geriatric population, rise in prevalence of cancer, surge in need for stem cell transplant, and others.

2) What would be the CAGR of the cell viability assays market over the forecast period?

Ans: The market size of cell viability assays is anticipated to attain a CAGR of 11.5% over the forecast period, i.e., 2024 â€“ 2036.

3) Who are the major players dominating the cell viability assays market?

Ans: The major players in the market are Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Merck KGaA, Becton, Dickinson and Company (BD), PerkinElmer Inc., Promega Corporation, Biotium, Inc., Creative Bioarray, Abcam Plc., and others.

4) Which segment captures the largest market size in the application segment in the cell viability assays market?

Ans: The stem cell research segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

5) Which region will provide more business opportunities for the growth of the cell viability assays market in the future?

Ans: The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Base Year	2023
Forecast Year	2024-2036
CAGR	~ 11.5%
Base Year Market Size (2023)	~ USD 5 Billion
Forecast Year Market Size (2036)	~ USD 19.7 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Cell Viability Assays Market Size & Share by Product (Consumables, Instrument); Application (Drug Discovery & Development, Stem Cell Research) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036